ArticleFrontiers in immunology2024
CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell influx and polarization.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Inflammation and Immune Mechanisms in Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- CD8Nature reviews. Cardiology · 2026Review
- M2 Macrophages derived exosomes promoted Periodontal ligament stem cells osteogenic differentiation through secreting CCL18.Clinics (Sao Paulo, Brazil) · 2026Article
- Atherosclerotic Fibrous Plaques in Women Present ECM Remodeling Linked to TGF-β.Circulation research · 2026Article
- Single-Cell Analysis, Spatial Transcriptomics and Molecular Docking Unveil Potential Therapeutic Targets for Carotid Atherosclerosis.Balkan medical journal · 2026Article
- The role of chemokines and their receptors in cardiovascular diseases.Frontiers in immunology · 2026Review
- Single cell spatial transcriptomics integration deciphers the morphological heterogeneity of atherosclerotic carotid arteries.Nature communications · 2025Article
- The secretome of senescent monocytes predicts age-related clinical outcomes in humans.Nature aging · 2025Article
- Exploring the causal links between inflammation-related genes and atherosclerosis through Mendelian randomization analysis.Medicine · 2025Article
- Machine Learning-Based Immuno-Inflammatory Index Integrating Clinical Characteristics for Predicting Coronary Artery Plaque Rupture.Immunity, inflammation and disease · 2025Article
- The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The CC chemokine ligand 18 (CCL18) is a chemokine highly expressed in chronic inflammation in humans. Recent observations of elevated CCL18 plasma levels in patients with acute cardiovascular syndromes prompted an investigation into the role of CCL18 in the pathogenesis of human and mouse atherosclerosis. Methods and results: CCL18 was profoundly upregulated in ruptured human atherosclerotic plaque, particularly within macrophages. Repeated administration of CCL18 in Western-type diet-fed Discussion: Our studies are the first to identify the CCL18/CCR6 axis as a regulator of immune responses in advanced murine and human atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.